The Role of Schizotypy in the Study of the Etiology of Schizophrenia Spectrum Disorders

Neus Barrantes-Vidal*,1,2,3, Phillip Grant5, and Thomas R. Kwapil2
1Departament de Psicologia Clínica i de la Salut, Universitat Autònoma de Barcelona, Spain; 2University of North Carolina at Greensboro, Greensboro, NC; 3Centre for Biomedical Research Network on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; 4Sant Pere Claver – Fundació Sanitària, Barcelona, Spain; 5Justus-Liebig-University Giessen, Giessen, Germany

*To whom correspondence should be addressed; Departament de Psicologia Clínica i de la Salut, Facultat de Psicologia (Edifici B), Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain; telephone: +34 93 5813864, fax: +34 93 5812125, e-mail: neus.barrantes@uab.cat

Schizotypy provides a useful construct for understanding the development of schizophrenia spectrum disorders. As research on the epidemiology of psychotic symptoms and clinical risk for psychosis has expanded, conceptual challenges have emerged to comprehend the nature and borders of the space comprised between personality variation and psychosis. Schizotypy is considered in light of these more recent constructs. It is suggested that rather than being superseded by them due to their higher specificity and predictive power for transition to psychosis, schizotypy integrates them as it constitutes a dynamic continuum ranging from personality to psychosis. The advantages of schizotypy for studying schizophrenia etiology are discussed (eg, it facilitates a developmental approach and the identification of causal, resilience, and compensating factors and offers a multidimensional structure that captures etiological heterogeneity). An overview of putative genetic, biological, and psychosocial risk factors is presented, focusing on commonalities and differences between schizotypy and schizophrenia spectrum disorders. The found notable overlap supports etiological continuity, and, simultaneously, differential findings appear that are critical to understanding resilience to schizophrenia. For example, discrepant findings in genetic studies might be interpreted as suggestive of sets of independent genetic factors playing a differential role in schizotypy and schizophrenia: some would influence variation specifically on schizotypy dimensions (ie, high vs low schizotypy, thereby increasing proneness to psychosis), some would confer unspecific liability to disease by impacting neural properties and susceptibility to environmental factors (ie, high vs low resilience to disorder) and some might contribute to disease–specific characteristics. Finally, schizotypy’s promise for studying gene-environment interactions is considered.

Key words: psychotic-like experiences/psychosis/psychosis proneness/risk factors/genetics/environment

Introduction

Schizotypy was introduced to represent the inherited vulnerability to schizophrenia spectrum disorders expressed as a multidimensional personality organization.1 The interaction of this vulnerability substrate with other genetic and environmental factors shapes the risk of presenting spectrum disorders and yields a wide range of phenotypic variance. Schizotypy is associated with heightened risk for the development of psychotic disorders.2,3 although most schizotypes are not expected to develop psychosis, and constitutes a useful framework to study etiological factors of schizophrenia spectrum disorders. Assessment of schizotypy provides an entry point for identifying individuals possessing liability to psychosis prior to the appearance of clinical manifestations. This should facilitate the study of developmental pathways to psychosis and the identification of protective factors in individuals not presenting with typical confounding factors associated with schizophrenia spectrum disorders.

The construct of schizotypy was developed both within the individual differences and medical traditions, which has led to differences in its conceptualization.4 The fully dimensional model of schizotypy, rooted in personality tradition, proposes schizotypy as part of normal personality, being a source of both healthy variation and predisposition to psychosis. This model encompasses the more restrictive conceptualization derived from the medical tradition that dimensionality in psychosis exists but is restricted to the severity of presentation (from personality

© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
pathology to the most extreme form of schizophrenia), viewing schizotypy as a *forme fruste* of psychosis (quasi-dimensional model). These models involve different views on the usefulness of schizotypy for studying schizophrenia spectrum disorders. The medical perspective tends to view schizotypy as a risk factor and a link in the chain towards schizophrenia. The reference point is the pathological, and the relevant focus is understanding the transition from subclinical stages to psychosis. From this perspective, studying nonclinical variation is not highly informative, and this has hindered integration of knowledge derived from the individual differences and clinical fields. This has also slowed down the adoption of a developmental psychopathology perspective in the field of psychosis (which recognizes continuity between normal and abnormal and puts the emphasis in the study of interindividual differences and processes contrary to traditional disease models of causation), even if a number of researchers pioneered a developmental conceptualization of schizophrenia in the early 90's. In other psychopathology domains, more fruitful research has been conducted to understand connections between personality and psychopathology. This possibly relates to challenges posed by the larger phenotypic discontinuity existing between trait and disorder in the case of psychosis compared with other domains, say trait anxiety and anxiety disorders, the failure of radical "Eysenckian dimensionalism" to recognize that there is a transition between healthy schizotypy *personality* and psychotic *illness states* (not meaning that they are unconnected), and that schizotypy presents more challenges than other personality dimensions (eg, definition of the low end of schizotypy).

This article focuses on how schizotypy can be informative for studying schizophrenia spectrum disorders. It first addresses currently unresolved conceptual issues regarding schizotypy and then offers a brief overview on candidate causal factors regarding commonalities and differences between schizotypy and schizophrenia spectrum disorders.

**Conceptual Issues**

*Has the Usefulness of Schizotypy in Etiological Research Been Superseded by New Constructs?*

As discussed in a previous article of this Special Issue, there are numerous terms referring to the psychopathological space between psychological health and psychosis. These terms variously refer to individual differences, subclinical manifestations, symptom-like experiences (eg, psychotic-like experiences [PLEs]), and clinical conditions closer to psychosis but vary in terms of severity, frequency, and duration (eg, schizotypal personality disorder [SPD], prodromal or at-risk mental states, and attenuated psychotic symptoms syndrome). These constructs have often been proposed as alternatives to schizotypy, although some have been used interchangeably with schizotypy. PLEs are traditionally defined as mild versions of psychotic symptoms, but are also used interchangeably with schizotypy. We suggest that, in most cases, these alternatives are narrower constructs interpretable as manifestations along the schizotypy continuum.

As epidemiological research on PLEs has expanded, there seem to be assumptions that PLEs are superior to schizotypy traits for assessing psychosis liability in nonclinical populations. We suggest, however, that this may reflect a misinterpretation that schizotypy simply taps incipient risk for psychosis. Indeed, PLEs are useful predictors of psychosis development, because ostensibly they are psychotic symptoms, albeit in milder form. Furthermore, we suggest that PLEs, like overt psychotic symptoms, can be thought of as manifestations of positive schizotypy. Simply put, PLEs are useful indicators of schizotypy and predictors of spectrum disorder and psychosis risk in nondisordered schizotypes (although only representing one schizotypy dimension).

PLEs are also suggested to be more advantageous than schizotypy, because they are less unspecific. It should be noted, however, that both schizotypy traits and PLEs are present in samples of mood disorder patients, predict mood disorders with psychotic features, and share genetic factors with neuroticism. In fact, this is consistent with the idea of positive schizotypy conveying expression of psychosis in both schizophrenia and mood psychoses. Rather than reflecting a lack of specificity, we believe schizotypy provides a useful mechanism for linking the experience of mood and non-mood psychoses. Furthermore, it highlights the importance of not establishing one-to-one associations between personality dimensions, subclinical states and *specific* disorders, as the early stages of psychopathology are not highly specific and interact dynamically with each other.

An aspect seeming to have created confusion is the dual nature of schizotypy (as any other dimension) having both state and trait manifestations. A useful analogy could be systemic disorders. Cardiovascular functioning, indexed partly by blood pressure, provides an analogy for schizotypy that is continuously distributed in the population. This trait though has a dual nature, as it also shows fluctuations according to a number of exogenous and endogenous factors, thus presenting with properties of a state. Schizotypy tends to be used to refer to the stable personality structure, whereas PLEs are used to describe temporal states that fluctuate according to developmental transient states (eg, neurodevelopmental reorganizations) and are subject to environmental influences. So, on the one hand, we ascribe stability to schizotypy because we conceive of personality as a *fixed* temperamental set of stable propensities, but then it does not seem to be a good model to track the developmental pathways to clinical disorders because it is sensitive to endogenous
and exogenous variation. Most likely the problem is that true dynamic and developmental models of personality and psychopathology are not still well established, even if the notion of a sharp distinction between temperament, personality, and psychopathology and the assumption that personality is fixed and lacks a state component have been questioned.17

Another issue is whether clinical risk models are superior to schizotypy for studying schizophrenia etiology, given they have better psychosis-specificity and predictive power. As referred to in a previous article in this special issue,9 the interpretation that schizotypy is a poor model because it has low predictive value derives from a misconception of schizotypy, as it is not expected that many individuals with high schizotypy will develop schizophrenia spectrum disorders. Furthermore, help-seeking individuals meeting clinical risk criteria have more severe psychopathology than those with subclinical symptoms in the community (comorbidity bias), so transition rates to psychosis are naturally higher in the clinically defined population.16 Interestingly, Salokangas et al18 found in ultra-high risk individuals that baseline self-reported schizotypy traits, specifically ideas of reference and lack of close interpersonal relationships, were associated with the risk of transition to psychosis. The co-occurrence of these schizotypy features doubled the risk of transition at 18 months, and this risk remained significant when controlling for a diagnosis of SPD.

So What Is the ‘Added Value’ of Schizotypy for the Study of Schizophrenia Etiology?

Schizotypy offers a number of advantages for conceptualizing the etiology, development, and expression of schizophrenia spectrum psychopathology. Firstly, it integrates a broad range of conditions including schizophrenia and related disorders, spectrum personality disorders, the prodrome and at-risk mental states, subclinical manifestations, and normal individual differences allowing for a dynamic developmental approach. This enables us to study a broad spectrum of variation, not just rare, and extreme manifestations like clinical disorders and the prodrome. This approach is consistent with NIMH Research Domain Criteria, which favor a bottom-up approach (from basic traits to higher order levels) of dimensional phenotypes.19 Also, this framework allows the identification of factors contributing to movement along the schizotypy continuum at subclinical and clinical levels, taking into consideration that there might be different mechanisms operating within different ranges of severity along the continuum, including those that trigger the onset of clinical disorders. The study of subclinical expression should avoid many of the serious consequences of schizophrenia spectrum disorders that confound etiological research, thereby enhancing the study of psychological variables easily confounded by symptoms, severity, distress, comorbidity, and maladaptive strategies to emerging symptoms. Finally, schizotypy enhances the power of genetic and endophenotype studies that previously omitted subclinical cases or misclassified them as unaffected.

In addition to integrating subclinical and clinical expressions, schizotypy also offers a multidimensional structure that captures the heterogeneity in the etiology, development, and expression of schizophrenia spectrum psychopathology. This heterogeneity and unique patterns of impairment in patients are not well explained by unitary models of schizotypy and schizophrenia. For example, positive schizotypy is characterized by affective dysregulation and negative schemas whereas negative schizotypy is characterized by diminished positive affect and reward, showing similar social difficulties but driven by differential mechanisms.20,21 Furthermore, this multidimensional model should enhance understanding of the overlap and differentiation between affective and nonaffective psychoses—specifically, suggesting that both psychoses are high on positive schizotypy, but only non-affective psychoses involve negative schizotypy.

Studying continuities and discontinuities between schizotypy and schizophrenia spectrum disorders should enhance understanding the heterogeneity in pathways to both clinical and nonclinical outcomes and help identify protective or compensating factors. The inclusion of nondisordered individuals who are putative risk carriers for schizophrenia spectrum disorders should enhance the search for resilience factors (the very concept of resilience relies on identification of individuals with risk factors who remain healthy). For example, it has been suggested that nondisordered schizotypy, SPD, and schizophrenia share left temporal volume reductions, suggesting common genetic vulnerability, whereas striatal and frontal lobe abnormalities are not consistently seen in high schizotypy and SPD, suggesting that they may involve compensatory or protective factors.22 Schizotypal and schizophrenic individuals may share a common genetic vulnerability that renders the temporal cortex particularly vulnerable to environmental insults. However, genetic or environmental factors that are different from those conferring susceptibility to schizophrenia, such as frontal lobe reserve or general intelligence, may decrease the impact of genetic susceptibility to schizophrenia and allow high schizotypy individuals to be more resistant to downstream effects of temporal dysfunction.22

A Brief Overview of Etiological Factors in Light of Continuities and Discontinuities Between Schizotypy and Schizophrenia Spectrum Disorders

In this section, we provide a brief overview of candidate etiological factors for schizotypy and schizophrenia. If schizotypy is the personality matrix that increases the risk of developing schizophrenia spectrum disorders, at least
part of the factors explaining schizotypy variance should also be associated with schizophrenia. Simultaneously, as schizophrenia spectrum disorders are not the necessary outcome of schizotypy (health or nonpsychotic maladaptations can be associated with it), it is expected that there will be factors explaining schizotypy variance but not associated with schizophrenia. The focus of this overview will be to note the overlap and differences between schizotypy and schizophrenia spectrum disorders. Additional articles in this special issue deal with associations of schizotypy with candidate endophenotypes and risk mechanisms.23,24

Genetic Factors
The common genetic basis of schizotypy and schizophrenia was believed to be a single dominant risk allele that, in interaction with environmental factors, leads to individual differences in schizotypy.1,23 Current opinion, however, is that about 8300 independent polymorphisms confer schizophrenia risk.28 These estimates have considerable implications regarding the taxonicity vs dimensionality debate, since a large number of contributing alleles supports the assumption of a continuous nature of schizotypy— which, as mentioned earlier, does not preclude the existence of a functional discontinuity between high schizotypy and schizophrenia.

As for concordance rates of schizophrenia spectrum diagnoses, values in schizotypy increase with higher genetic similarity to schizophrenics. A review28 indicated that relatives of patients primarily show elevated social-anhedonia, although others also find it co-occurring with higher perceptual aberration.38 Regarding the Schizotypal Personality Questionnaire (SPQ), the val-allele appears more heavily related to increases in positive schizotypy.47 thus, rs4680 is indeed relevant for schizotypy, but further research in significantly larger samples is necessary to identify exactly which features are age-specifically related to which allele; this question is currently being examined by us in an international sample comprised of most samples from the aforementioned individual articles.

Additionally, other dopamine-related genes show associations with schizotypy, such as DRD2, SLC6A3, 46,44, and MAOA.36 Furthermore, changes in expression patterns of dopamine-relevant genes are often reported in schizophrenia,45,46 and a recent study shows that expression patterns of a number of these genes in human blood correlate with positive schizotypy.47

Other genes implicated in the etiology of schizophrenia have also been found to be associated with schizotypy, including NRG1,48 RGS4,49 PRODH,50 BDNF, 50, and ZNF804A.51,52 Individual studies suggest both an interaction between individual polymorphisms as well as additive effects.53 However, many of the aforementioned genes (with the exception of DRD2 and ZNF804A) no longer appear as significant hits in the latest schizophrenia Genome-Wide Association Study (GWAS).54 This underpins the usefulness of schizotypy as a research framework for schizophrenia: A critical issue of GWAS is the treatment of both cases and controls as homogeneous groups, as nondisordered schizotypes would be in the comparison group despite carrying the presumptive underlying vulnerability for schizophrenia. Additionally, all schizotypic variance within both groups is ignored. Furthermore, it must be considered that “negative studies should never be weighted as strongly as positive ones” and “researchers need to look at the cumulative evidence for a gene’s involvement, be it genetic or biological.”55

Thus, polymorphisms not related to schizophrenia in GWAS, but consistently and plausibly linked to schizotypy, should not be easily dismissed. Grant56 has suggested that there are at least 2 groups of genetic factors. The first group mainly explains schizotypy variance and increases proneness for psychosis. The second group, which marks the risk of transition between high but healthy schizotypy and clinical schizophrenia, is probably independent of schizotypy, but conveys unspecific neuronal resilience. Thus, it is extremely likely in case-control designs that SNPs explaining small schizotypic variance (both between and within groups) are lost due to the potentially far stronger effects of SNPs that explain the transition between healthy high schizotypy and schizophrenia. In other words, effects of SNPs that strongly but unspecifically influence whether a
person will be healthy or sick may overshadow the effects of SNPs that have specific but individually weak effects on schizotypic variance.

Further support for this hypothesis is given by the nature and function of the genes identified by GWAS. There is currently no theoretical basis for many of the identified SNPs, most of them only reach genome-wide significance when samples from bipolar patients are included, most are involved in basal cellular metabolism, and many are well established as risk factors for unrelated somatic conditions. Recently, Ripke et al published new results, identifying 108 schizophrenia-associated loci (83 being new). Thus, further study of these 108 genetic markers is necessary regarding their role in schizotypy and their specificity to the psychosis continuum.

Two studies investigating the relation of a polygenic risk score derived from GWAS indicate inverse associations with PLEs and schizotypy (Hatzimanolis et al, in prep; Athens Study of Psychosis Proneness and Incidence of Schizophrenia [ASPIS]) in healthy participants; that is, high polygenic risk was associated with less PLEs and lower schizotypy scores. In both studies, single genes did not account for differences in schizotypy or psychotic experiences, but there was a trend for an association of the gene ZNF804A in the direction previously reported for schizophrenia and schizotypy. Considering that the studies only included healthy participants, there might be an involuntary sampling bias in these studies, as those individuals with high polygenic risk scores and high schizotypic traits would be more likely to develop spectrum conditions than to be in a healthy sample, whereas those persons with high but healthy schizotypy should have a lower polygenic risk score. If one assumes 2 independent factors, namely schizotypy and health resilience, then it is plausible to propose that individuals with high schizotypy and low resilience would rarely be in the healthy population but, rather, develop schizophrenia. Thus, a polygenic risk score comprised of many genetic variations involved in a number of medical conditions (and therefore unlikely to be specific to schizotypy) should actually be inversely related to schizotypy in nonpatients. In sum, this would suggest that the association between genetic risk and schizotypy is not generally inverse compared to schizophrenia, but rather differentially related, depending on the function of individual genes; thus, lack of genetic susceptibility for disease is protective for healthy schizophrenics. Vice versa, genetically based low resilience may incur risk for a number of medical conditions, but only coincidentally high genetic schizotypy markers would lead to an incidence of schizophrenia.

**Biological Environmental Factors**

As mentioned previously, heritability studies estimate that genetic factors explain about 50% of schizotypic variance. The remaining variance is explained by environmental factors that can be roughly divided into psychosocial and (neuro-) biological factors.

Supporting neurodevelopmental models, many biological environmental factors are consistently shown to be involved in schizophrenia development; especially antenatal maternal viral infections, obstetric complications, elevated stress hormones, advanced parental age, and cannabis use. Some of these factors have also been investigated regarding schizotypy, most notably in large Finnish studies. A number of pre- and perinatal complications have been associated with schizotypy. A large study found that individuals whose mothers had been exposed to influenza during the H3N2-epidemic in 1969 while in the sixth gestational month presented with higher schizotypy as adults. Additionally, obstetric complications and low birth weight are associated with retrospective childhood schizotypal traits in adult schizophrenia spectrum patients and with schizotypy. Others found effects of lower birth and/or placental weight as well as head circumference, but only in women and limited to positive schizotypy traits. Associations of maternal diabetes and viral infections (especially in the first and second trimester) with PLEs in adults are also reported, but the numbers of affected individuals are minor in comparison to the numbers of individuals with identical complications without PLEs. Finally, examination of other birth-related factors with regard to schizotypy showed no associations, although 60% of individuals within the high-schizotypy group reporting a schizophrenia spectrum diagnosis were born in winter.

Cannabis use has been extensively studied in cross-sectional and longitudinal designs in healthy samples. Overall, findings indicate associations of schizotypy and PLEs with cannabis use and earlier age of initiation of use, although there are also contrary findings. The association is found for the positive and disorganized but not for the negative dimension. As for the temporal sequence, some longitudinal and age-stratified studies suggest inverse causality, namely that the development of schizotypy influences the subsequent use of drugs. Also, studies controlling for effects of childhood schizotypy find that the effect of cannabis on PLEs is reduced when childhood schizotypy is included in the model. It should be noted, however, that both studies cannot fully exclude the possibility of early childhood “oddness” playing a role in the onset of cannabis use.

Finally, a number of studies examined links between indicators of early developmental insults and schizotypy. Hereof, neurological soft signs connected with schizophrenia were found mainly to correlate with negative but also with positive and disorganized schizotypy. Also, dermatoglyphic anomalies have been associated with positive and negative schizotypy as well as SPD. These findings add to the understanding that schizotypy also shares a common nongenetic biological continuum with schizophrenia.
Growing research on the effects of psychosocial adversities on the brain is challenging the assumption that endophenotypic anomalies identified in schizotypy and schizophrenia only result from genetic and biological factors. For example, early life stress/maltreatment has been found to produce brain functional and structural alterations, and there is evidence from animal models indicating that certain environmental exposures can cause behavioral and brain phenotypes analogous to those observed in schizophrenia.

A substantial body of work has shown that a range of social and interpersonal environmental factors are associated with schizophrenia and schizotypy, with evidence appearing to be more robust for the positive dimension (reviews in). Although some findings are conflicting and demonstration of a causal status is challenging, increasing agreement is emerging that psychosocial factors are not mere triggers of a genetic vulnerability but rather coparticipating factors in the psychosis continuum. Specifically, it has been suggested that epigenetic mechanisms might mediate environmental effects on gene function by ‘switching’ on and off gene transcription throughout development, constituting a mechanism for rapid genome adaptations to the environment.

In terms of macroenvironmental factors, there is strong evidence linking urbanicity during development with increased likelihood of both psychosis and PLEs, with dose-response relationship reported in a number of studies. The association of schizophrenia and poverty has been mixed, even if poverty seems more strongly associated with psychosis than with other psychiatric conditions. Furthermore, poverty showed a unique association with SPD dimensional scores in a general population survey examining all Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) personality disorders. An association has also been reported between socioeconomic disadvantage and risk for delusional–like experiences.

Accumulating evidence indicates that minority position has an important role. Migrant status has been associated with increased risk for psychotic disorder as well as with greater prevalence of PLEs. The risk for psychotic disorder is increased in both first- and second-generation immigrants, suggesting that the post-migration context, rather than migration itself, may have a more prominent role. For example, the extent to which an individual at risk of experiencing exclusion/discrimination is an exception with regard to the greater social environment has been suggested as a mechanism underpinning the increased rates of psychotic phenomena in ethnic minority individuals. Thus, ethnic minority individuals living in areas with high levels of ethnic density appear to have a protective effect in relation to psychotic disorders and experiences.

As for microenvironmental risk factors, a meta-analysis of 20 studies showed that parental communication deviance is associated with heightened risk for psychosis and perceptions of parental behavior, particularly lower perceived care, are also related to psychotic disorders and schizotypy traits. One of the most researched interpersonal factors is childhood adversity, with a recent meta-analysis indicating that trauma increases the risk of psychosis (including both clinical and subclinical expressions) with an odds ratio of 2.78. Childhood abuse, neglect, and bullying have all been linked to schizotypy, with some studies having controlled for relevant potential confounders (eg, family history of psychosis) and using prospective designs (reviews in). In general, the evidence suggests that experiences involving an “intention to harm” element appear more strongly related to psychotic symptoms and experiences than adversities of a nonintentional nature, like the death of a close person.

Conclusions

Overall, schizotypy and schizophrenia seem to have a substantial overlap in terms of etiological factors at the genetic, biological, and psychosocial levels, which support the notion of not only phenomenological but also etiological continuity and the claim that schizotypy is a useful framework to investigate both normal individual differences and the etiology of schizophrenia spectrum disorders. Additionally, some differential findings were found, which are as relevant as similarities in order to define a complete account of the schizophrenia spectrum and to identify protective factors. The overview of recent genetic studies supported that there might be sets of independent factors playing a differential role in schizotypy and schizophrenia; some would influence variation specifically on schizotypy dimensions (ie, high vs low schizotypy), some would confer unspecific susceptibility to disease by impacting neural properties and susceptibility to environmental insults (ie, high vs low resilience) and still some might contribute to disease-specific characteristics. In addition, complex patterns of gene–gene, environment–environment, and gene–environment interactions likely contribute to shape differential liability to clinical disorders, as suggested by the fact that the majority of individuals carrying genetic risk or exposed to environmental risk do not exhibit elevated rates of schizotypy or schizophrenia spectrum disorders. The study of differential effects of the same environmental factors in genetically diverse individuals (gene–environment–interaction) is challenging, but has already shown its potential to understand the development of spectrum disorders. Schizotypy provides a useful construct for studying gene–environment effects because it broadens the phenotype (and avoids misclassification of nondisordered schizotypes as unaffected), allows for the examination of etiological factors without the confounds of the
N. Barrantes-Vidal et al

consequences of schizophrenia, enhances identification of protective mechanisms by including the nondisordered members of the schizophrenia spectrum phenotype and, thus, promises to increase the power of such studies.

Funding

The Spanish Ministerio de Economía y Competitividad (PSI2011-30321-C02-01); Fundació La Marató de TV3 (091110); Generalitat de Catalunya (2014SGR1070) to N.B.V. and T.R.K. The Institució Catalana de Recerca i Estudis Avançats (ICREA Acadèmia Award) to N.B.V.

Acknowledgments

The authors have declared that there are no conflicts of interest in relation to the subject of this study.

References

1. Meehl PE. Schizotaxia, schizotypy, schizophrenia. *Am Psychol.* 1962;17:827–838.
2. Kwapil TR, Gross GM, Silvia PJ, Barrantes-Vidal N. Prediction of psychopathology and functional impairment by positive and negative schizotypy in the Chapmans’ ten-year longitudinal study. *J Abnorm Psychol.* 2013;12:807–815.
3. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. *Arch Gen Psychiatry.* 2000;57:1053–1058.
4. Claridge G. Theoretical background and issues. In: Claridge G, ed. *Schizotypy – Implications for Illness and Health.* Oxford, NY: Oxford University Press; 1997:3–18.
5. Debbané M, Barrantes-Vidal N. Schizotypy from a developmental perspective. *Schizophr Bull.* 2015;41(suppl 2):S386–S395.
6. Walker EF, ed. *Schizophrenia: A Life-Course Developmental Perspective.* San Diego, CA: Academic Press; 1990.
7. Gooding D, Iacono, WI. Schizophrenia through the lens of a developmental psychopathology perspective. In: Cicchetti D, Cohen DJ, eds. *Manual of Developmental Psychopathology, Risk, Disorder, and Adaptation*, Vol II. New York, NY: Wiley; 1995:535–580.
8. Widiger T. Personality and psychopathology. *World Psychiatry.* 2011;10:103–105.
9. Kwapil TR, Barrantes-Vidal N. Schizotypy: Looking back and moving forward. *Schizophr Bull.* 2015;41(suppl 2):S366–S373.
10. Chapman L, Chapman J. Scales for rating psychotic and psychotic-like experiences as continua. *Schizophr Bull.* 1980;6:476–489.
11. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. *Psychol Med.* 2009;39:179–195.
12. Kwapil TR, Chapman LJ, Chapman J. Validity and usefulness of the Wisconsin manual for assessing psychotic-like experiences. *Schizophr Bull.* 1999;25:363–375.
13. Varghese D, Scott J, Welham J, et al. Psychotic-like experiences in major depression and anxiety disorders: a population-based survey in young adults. *Schizophr Bull.* 2011;37:389–393.
14. Dunayevich E, Keck PE Jr. Prevalence and description of psychotic features in bipolar mania. *Curr Psychiatry Rep.* 2000;2:286–290.
15. Macare C, Bates TC, Heath AC, Martin NG, Ettinger U. Substantial genetic overlap between schizotypy and neuroticism: a twin study. *Behav Genet.* 2012;42:732–742.
16. van Os J. The dynamics of subthreshold psychopathology: implications for diagnosis and treatment. *Am J Psychiatry* 2013;170:695–698.
17. Clark AL. Temperament as a unifying basis for personality and psychopathology. *J Abnorm Psychol* 2005;114:505–521.
18. Salokangas RK, Dingemans P, Heinimaa M, et al. Prediction of psychosis in clinical high risk patients by the Schizotypal Personality Questionnaire. *Eur Psychiatry* 2013;28:469–475.
19. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. *BMC Med.* 2013;11:126.
20. Kwapil TR, Brown LH, Silvia PJ, Myin-Germeys I, Barrantes-Vidal N. The expression of positive and negative schizotypy in daily life: an experience sampling study. *Psychol Med.* 2012;42:2555–2566.
21. Barrantes-Vidal N, Gross GM, Sheinbaum T, Mitjavila M, Ballespi S, Kwapil TR. Positive and negative schizotypy are associated with prodromal and schizophrenia-spectrum symptoms. *Schizophr Res.* 2013;145:50–55.
22. Rosell DR, Futterman SE, McMaster A, Siever LJ. Schizotypal personality disorder: a current review. *Curr Psychiatry Rep.* 2014;16:452.
23. Cohen AS, Mohr C, Ettinger U, Chan RCK, Park S. Schizotypy as an organizing framework for social and affective sciences. *Schizophr Bull.* 2015;41(suppl 2):S427–S435.
24. Ettinger U, Mohr C, Gooding DC, et al. Cognition and brain function in schizotypy: a selective review. *Schizophr Bull.* 2015;41(suppl 2):S417–S426.
25. Rado S. Dynamics and classification of disordered behavior. *Am J Psychiatry.* 1953;110:406–416.
26. Ripke S, O’Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet.* 2013;45:1150–1159.
27. Plomin R, Haworth CM, Davis OS. Common disorders are quantitative traits. *Nat Rev Genet.* 2009;10:872–878.
28. Tarbox SI, Pogue-Geile MF. A multivariate perspective on schizotypy and familial association with schizophrenia: a review. *Clin Psychol Rev.* 2011;31:1169–1182.
29. Baron M, Gruen R, Asins L, Kane J. Familial relatedness of schizophrenia and schizotypal states. *Am J Psychiatry.* 1983;140:1437–1442.
30. Battaglia M, Bernardeschi L, Franchini L, Bellodi L, Smeraldi E. A family study of schizotypal disorder. *Schizophr Bull.* 1995;21:33–45.
31. Kendler KS, Walsh D. Schizotypal personality disorder in parents and the risk for schizophrenia in siblings. *Schizophr Bull.* 1995;21:47–52.
32. Linney YM, Murray RM, Peters ER, MacDonald AM, Rijsdijk F, Sham PC. A quantitative genetic analysis of schizotypal personality traits. *Psychol Med.* 2003;33:803–816.
33. Kendler KS, Hewitt J. The structure of self-report schizotypy in twins. *J Pers Disord.* 1992;6:1–17.
34. Hay DA, Martin NG, Foley D, Trelora SA, Kirk KM, Heath AC. Phenotypic and genetic analyses of a short measure of
psychosis-proneness in a large-scale Australian twin study. *Twin Res.* 2001;4:30–40.
35. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. *Pharmacogenetics.* 1996;6:243–250.
36. Grant P, Kuepper Y, Mueller E, Wielpuetz C, Mason O, Hennig J. Dopaminergic foundations of schizotypy as measured by the German version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE) - a suitable endophenotype of schizophrenia. *Front Hum Neurosci.* 2013;7.
37. Docherty AR, Sponheim SR. Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia. *J Abnorm Psychol.* 2008;117:788–798.
38. Avramopoulos D, Stefanis NC, Hantoumi I, Smyrnis N, Evdokimidis I, Stefanis CN. Higher scores of self-reported schizotypy in healthy young males carrying the COMT high activity allele. *Mol Psychiatry.* 2002;7:706–711.
39. Schürhoff F, Szöke A, Chevalier F, et al. Schizotypal dimension: an intermediate phenotype associated with the COMT high activity allele. *Am J Med Genet B Neuropsychiatr Genet.* 2007;144B:64–68.
40. Smyrnis N, Avramopoulos D, Evdokimidis I, Stefanis CN, Tsekou H, Stefanis NC. Effect of schizotypy on cognitive performance and its tuning by COMT val158 met genotype variations in a large population of young men. *Biol Psychiatry.* 2007;61:845–853.
41. Sheldrick AJ, Krug A, Markov V, et al. Effect of COMT val158met genotype on cognition and personality. *Eur Psychiatry.* 2008;23:385–389.
42. Grant P, Munk AJL, Kuepper Y, Wielpuetz C, Hennig J. Additive genetic effects for schizotypy support a fully-dimensional model of psychosis-proneness. *J Indiv Differ.* In press.
43. Taurisano P, Romano R, Mancini M, et al. Prefrontal-striatal physiology is associated with schizotypy and is modulated by a functional variant of DRD2. *Front Behav Neurosci.* 2014;8:235.
44. Ettinger U, Joober R, DE Guzman R, O’driscoll GA. Schizotypy, attention deficit hyperactivity disorder, and dopamine genes. *Psychiatry Clin Neurosci.* 2006;60:764–767.
45. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. *Mol Psychiatry.* 2005;10:40–68.
46. de Jong S, Boks MP, Fuller TF, et al. A gene co-expression network in whole blood of schizophrenics is independent of antipsychotic-use and enriched for brain-expressed genes. *PLoS One.* 2012;7:e39498.
47. Grant P, Gabriel F, Kuepper Y, Wielpuetz C, Hennig J. Psychosis-proneness correlates with expression levels of dopaminergic genes. *Eur Psychiatry.* 2014;29:304–306.
48. Lin CC, Su CH, Kuo PH, Hsiao CK, Soong WT, Chen WJ. Genetic and environmental influences on schizotypy among adolescents in Taiwan: a multivariate twin/sibling analysis. *Behav Genet.* 2007;37:334–344.
49. Stefanis NC, Trikalinos TA, Avramopoulos D, et al. Association of RGS4 variants with schizotypy and cognitive endophenotypes at the population level. *Behav Brain Funct.* 2008;4:46.
50. Ma X, Sun J, Yao J, et al. A quantitative association study between schizotypal traits and COMT, PRODH and BDNF genes in a healthy Chinese population. *Psychiatry Res.* 2007;153:7–15.
51. Yasuda Y, Hashimoto R, Ohi K, et al. Impact on schizotypal personality trait of a genome-wide supported psychosis variant of the ZNF804A gene. *Neurosci Lett.* 2011;495:216–220.
52. Stefanis NC, Hatzimanolis A, Avramopoulos D, et al. Variation in psychosis gene ZNF804A is associated with a refined schizotypy phenotype but not neurocognitive performance in a large young male population. *Schizophr Bull.* 2013;39:1252–1260.
53. Meyer BM, Huenem J, Rabl U, et al. October 16, 2014. Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults. *Brain Struct Funct.*
54. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature.* 2014;511:421–427.
55. McCaffrey P. Schizophrenia Genetics: Best of Times... Worst of Times? http://www.schizophreniaforum.org/images/SRFSchizophreniaGeneticsSeries.pdf. Accessed March 16, 2010.
56. Grant P. Genetic associations: the basis of Schizotypy. In: Mason O, Claridge G, eds. *Schizotypy – New Dimensions.* Oxford, UK: Routledge. In press.
57. Zammit S, Hamshere M, Dwyer S, et al. A population-based study of genetic variation and psychotic experiences in adolescents. *Schizophr Bull.* 2014;40:1254–1262.
58. Matheson SL, Shepherd AM, Laurens KR, Carr VJ. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. *Schizophr Res.* 2011;133:133–142.
59. Schmitt A, Malchow B, Hasan A, Falkai P. The impact of environmental factors in severe psychiatric disorders. *Front Psychiatry.* 2014;8:19.
60. Lahti J, Raikkonen K, Sovio U, et al. Early-life origins of schizotypal traits in adulthood. *Br J Psychiatry.* 2009;195:132–137.
61. Machón RA, Huttunen MO, Mednick SA, et al. Adult schizotypal personality characteristics and prenatal influenza in a Finnish birth cohort. *Schizophr Res.* 2002;54:7–16.
62. Foerster A, Lewis SW, Owen MJ, Murray RM. Low birth weight and a family history of schizophrenia predict poor premorbid functioning in psychosis. *Schizophr Res.* 1991;5:13–20.
63. Bakan P, Peterson K. Pregnancy and birth complications: A risk factor for schizotypy. *J Pers Disord.* 1994;8:299–306.
64. Zammit S, Odd D, Horwood J, et al. Investigating whether adverse prenatal and perinatal events are associated with non-clinical psychotic symptoms at age 12 years in the ALSpac birth cohort. *Psychol Med.* 2009;39:1457–1467.
65. Cohen AS, Najović GM. Birth characteristics and schizotypy: evidence of a potential “second hit.” *J Psychiatr Res.* 2011;45:955–961.
66. Compton MT, Chien VH, Bollini AM. Associations between past alcohol, cannabis, and cocaine use and current schizotypy among first-degree relatives of patients with schizophrenia and non-psychiatric controls. *Psychiatr Q.* 2009;80:143–154.
67. Skinner R, Conlon L, Gibbons D, McDonald C. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care. *Acta Psychiatr Scand.* 2011;123:21–27.
68. Barkus E, Stirling J, Hopkins R, Lewis S. The presence of neurological soft signs along the psychosis proneness continuum. *Schizophr Bull.* 2006;32:573–577.
69. Barkus EJ, Stirling J, Hopkins RS, Lewis S. Cannabis-induced psychosis-like experiences are associated with high schizotypy. *Psychopathology*. 2006;39:175–178.

70. Cohen AS, Buckner JD, Najolia GM, Stewart DW. Cannabis and psychiatrically-defined schizotypy: use, problems and treatment considerations. *J Psychiatr Res*. 2011;45:548–554.

71. Kwapil TR. A longitudinal study of drug and alcohol use by psychosis-prone and impulsive-nonconforming individuals. *J Abnorm Psychol*. 1996;105:114–123.

72. Schiffman J, Nakamura B, Earleywine M, LaBrie J. Symptoms of schizotypy precede cannabis use. *Psychiatry Res*. 2005;134:37–42.

73. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. *BMJ*. 2002;325:1212–1213.

74. Anglin DM, Corcoran CM, Brown AS, et al. Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. *Schizophr Res*. 2012;137:45–49.

75. Kaczorowski JA, Barrantes-Vidal N, Kwapil TR. Neurological soft signs in psychometrically identified schizotypy. *Schizophr Res*. 2009;115:293–302.

76. Theleritis C, Vitoratou S, Smyrnis N, et al. Neurological soft signs and psychometrically identified schizotypy in a sample of young conscripts. *Psychiatr. Res*. 2012;198:241–247.

77. Mechri A, Gassab L, Stama H, et al. Neurocognitive soft signs and schizotypal dimensions in unaffected siblings of patients with schizophrenia. *Psychiatry Res*. 2010;175:22–26.

78. Chok JT, Kwapil TR, Scheuermann A. Dermatoglyphic anomalies in psychometrically identified schizotypic young adults. *Schizophr Res*. 2005;72:205–214.

79. Barrantes-Vidal N, Fañanás L, Rosa A, Caparrós B, Dolors Riba M, Obiols JE. Neurocognitive, behavioural and neurodevelopmental correlates of schizotypy clusters in adolescents from the general population. *Schizophr Res*. 2003;61:293–302.

80. Weinsten DD, Diforio D, Schiffman J, et al. Minor physical anomalies, dermatoglyphic asymmetries, and cortical levels in adolescents with schizotypal personality disorder. *Am J Psychiatry*. 1999;156:617–623.

81. Teicher MH, Andersen SL, Polcari A, Anderson CM, Navalta CP, Kim DM. The neurobiological consequences of early stress and childhood maltreatment. *Neurosci Biobehav Rev*. 2003;27:33–44.

82. Brown AS. The environment and susceptibility to schizophrenia. *Prog Neurobiol*. 2007;82:304–328.

83. Bentall RP, Fernyhough C. Social predictors of psychotic experiences: specificity and psychological mechanisms. *Schizophr Bull*. 2008;34:1012–1020.

84. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. *Nature*. 2010;468:203–212.

85. Barrantes-Vidal N. Trauma and psychosis: Is it easier to study quarks than subjective meaning? *Acta Psychiatr Scand*. 2014;129:478–479.

86. van Winkel R, van Nierop M, Myin-Germeys I, van Os J. Childhood trauma as a cause of psychosis: linking genes, psychology, and biology. *Can J Psychiatry*. 2013;58:44–51.

87. Binbay T, Drukker M, Elbi H, et al. Testing the psychosis continuum: differential impact of genetic and nongenetic risk factors and comorbid psychopathology across the entire spectrum of psychosis. *Schizophr Bull*. 2012;38:992–1002.

88. Pedersen CB, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. *Arch Gen Psychiatry*. 2001;58:1039–1046.

89. Read J. Can poverty drive you mad? ‘Schizophrenia’, socioeconomic status and the case for primary prevention. *New Zealand J Psychol*. 2010;39:7–19.

90. Hengartner MP, Ajdacic-Gross V, Rodgers S, Müller M, Rössler W. Childhood adversity in association with personality disorder dimensions: new findings in an old debate. *Eur Psychiatry*. 2013;28:476–482.

91. Saha S, Scott JG, Varghese D, McGrath JJ. Socio-economic disadvantage and delusional-like experiences: a nationwide population-based study. *Eur Psychiatry*. 2013;28:59–63.

92. Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. *Psychol Med*. 2011;41:897–910.

93. van Os J. Psychotic experiences: Disadvantaged and different from the norm. *Br J Psychiatry*. 2012;201:258–259.

94. Boydl J, van Os J, McKenzie K, et al. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. *BMJ*. 2001;323:1336–1338.

95. Das-Munshi J, Bécares L, Boydell JE, et al. Ethnic density as a buffer for psychotic experiences: findings from a national survey (EMPIRIC). *Br J Psychiatry*. 2012;201:282–290.

96. de Sousa P, Varese F, Sellwood W, Bentall RP. Parental communication and psychosis: a meta-analysis. *Schizophr Bull*. 2014;40:756–768.

97. Meins E, Jones S R, Fernyhough C, Hurndall S, Koronis P. Attachment dimensions and schizotypy in a non-clinical sample. *Pers Indiv Differ*. 2008;44:1000–1011.

98. Varese F, Smets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. *Schizophr Bull*. 2012;38:661–671.

99. Sheinbaum T, Barrantes-Vidal N. Mechanisms mediating the pathway from environmental adversity to psychosis-proneness. In: Mason O, Claridge G, eds. *Schizotypy: New Dimensions*. Oxford, UK: Routledge. In press.

100. Velikonja T, Mason O, Fisher HL. Childhood trauma and schizotypy. In: Mason O, Claridge G, eds. *Schizotypy: New Dimensions*. Oxford, UK: Routledge. In press.

101. van Nierop M, Lataster T, Smeets F, et al. Psychopathological mechanisms linking childhood traumatic experiences to risk of psychotic symptoms: analysis of a large, representative population-based sample. *Schizophr Bull*. 2014;40 (suppl 2):S123–S130.

102. European Network of National Networks studying Gene-Environment Interactions in Schizophrenia. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. *Schizophr Bull*. 2014;40:729–736.

103. Modinos G, Iyegebe C, Prata D, et al. Molecular genetic gene-environment studies using candidate genes in schizophrenia: a systematic review. *Schizophr Res*. 2013;150:356–365.